In many medical applications, combining information from multiple biomarkers could yield a better diagnosis than any single one on its own. When there is a lack of a gold standard, an algorithm of classifying subjects into the case and non-case status is necessary for combining multiple markers. The aim of this paper is to develop a method to construct a composite test from multiple applicable tests and derive an optimal classification rule under the absence of a gold standard. Rather than combining the tests, we treat the tests as a sequence. This sequential composite test is based on a mixture of two multivariate normal latent models for the distribution of the test results in case and non-case groups and the optimal classification rule is derived returning the greatest sensitivity at a given specificity. This method is applied to a real data example and simulation studies have been carried out to assess the statistical properties and predictive accuracy of the proposed composite test. This method is also attainable to implement nonparametrically.
E2 antibodies and the prolonged survival from HIV in subjects without GBV-C viraemia has also been observed [5] . To detect the presence of E2 antibodies in human serum samples, one commonly used method is through the Enzyme Linked Immunosorbent Assay (ELISA); however, there is no commercial and validated test available for the E2 antibodies. In the motivating example from Dr. Jack Stapleton's lab at the University of Iowa, a total of 100 independent blood specimens obtained from HIV infected subjects were tested by two ELISAs, which are not perfect and return a quantitative result with respect to the concentration of the E2 antibodies. The primary goal of the paper is to establish and evaluate a composite diagnostic test based on the two ELISAs in the absence of the true antibody status and any other reference test.
In diagnostic testing, a gold standard is defined as a reference test or a benchmark that is assumed 100% accurate in discriminating case from non-case. When a gold standard is available, the accuracy of a single diagnostic test has been well studied. The accuracy of a binary test is evaluated by the true positive fraction (TPF, or sensitivity) and false positive fraction (FPF, or 1-specificity). For a continuous-scale test, different binary tests can be induced by selecting different threshold values. At each threshold, a pair of TPF and FPF is obtained, and the curve that connects all pairs of TPF and FPF over all possible thresholds, which is the receiver operating characteristic (ROC) curve, is a commonly used tool to evaluate a continuous marker. These are detailed in Zhou et. al. [20] and Pepe [21] .
When there are multiple imperfect tests available, combining them into one composite test may yield a better diagnostic test than any single test. For continuous tests, a simple case is to repeat testing on a single test. Tolley et. al. [22] and Murtaugh [23] consider the scenario of repeated applications of the same continuous test. At each test application, the threshold remains the same. For a set of different tests, various composite tests exist for a given overall specificity. The most straightforward way is to form a linear combination. Suppose X ∼ N (µ x , Σ x ) represents the test results in the case population and Y ∼ N (µ y , Σ y ) represents the test results in the non-case population. The linear composite rule is then based on U = a T X and V = a T Y . Su and Liu [24] justifies that the linear discriminant function is the optimal linear combination that produces the maximum AUC in this case, i.e., the coefficient for the best linear combination is
The linear combination is easy to implement and straightforward to interpret, however, the optimality is only guaranteed when the results are normal and homoscedastic. Rather combining the multiple tests in parallel, we could also treat them as a sequence. Thompson [25] considers the combination of a sequence of tests. The sequence of tests can be the repeated applications of the same test on the same subject, or different tests simultaneously. The development of the sequential rule does not limit to the linear combination of multiple tests, and the application of the sequential rule on a new population does not require the practice of all tests on each subject. Two main concepts are usually used to define the sequential rule [26, 27] . The first one is "believe negative" (BN), where individuals who have negative diagnosis from any particular test will not receive subsequent tests. The other one is "believe positive" (BP), where individuals who have positive diagnosis from any particular test will not receive sub sequential tests. In this work, we will focus on the sequential rule defined by the BP approach. Thompson [25] provides the evaluation of accuracy of a sequence of tests. For two continuous tests X 1 and X 2 , based on the BP rule, an individual is defined as positive if X 1 > c 1,p1 or X 2 > c 2,p2 , where c i,pi is the p i th percentile of the distribution of X i in non-case population for i = 1, 2. The ROC curve of the sequence test as a function of an overall false positive fraction s can be expressed as (1) [25] .
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where F 2.1D and F 2.1D are the conditional distribution functions for X 2 given X 1 < c 1p1 in the case and non-case populations. The accuracy of the test sequence could be assessed by the MaxROC curve expressed as
so that the sensitivity for any given specificity will be at least as high as that for either of the individual tests, applied on its own with the same threshold. The choice of threshold in implementation, however, is not addressed in this paper. Both the aforementioned combinations are based on the knowledge of a gold standard, or the true case status. In practice, such information is not always available, because it may be difficult or even impossible to determine the true case status, and even the available reference test against which new tests are compared is subject to error. Kraemer [28] argues the opinion that the true case status is almost never ascertained. For ordinal or continuous-scale tests, the sensitivity and specificity are computed based on a certain classification rule with a specific threshold value, hence are dependent on the choice of the classification rule. When the true case status is unknown and there is no gold standard or even an imperfect binary reference test, like the E2 antibodies data example, a decision rule established from multiple imperfect test needs to be studied [21] . The statistical issues in diagnostic testing without a gold standard are addressed by Hui and Walter [29] mainly focusing on binary tests and summarized by Hui and Zhou [30] with many available methods for quantitative tests. Using the finite mixture model for continuous data , one could acquire the pointwise estimates of the sensitivity and specificity for a continuous-scale test over all possible threshold values by the maximum likelihood method [31] . The estimated ROC curve composed by all estimated sensitivities and specificities, however, may not retain the monotonicity, as in Figures. 2, 3 , 4, 5 of [31] . Henkelman et al. [32] propose an estimation of the ROC curve of an ordinal-scale test via a mixture of multivariate normal latent model and Choi et al. [33] provide a parametric Bayesian method for a continuous-scale test under the same distributional assumption. Both methods guarantee that the estimated ROC curve is monotone. The ROC curve can also be estimated nonparametrically instead of assuming the multivariate normal distributions as proposed by Hall and Zhou [34] in which the monotonicity of the estimated ROC curve is assured without any parametric assumptions on the distributions of the test results.
The methods above primarily focus on the evaluation of diagnostic tests when there is no definitive diagnosis or a gold standard, rather on the formulation of a decision rule by combining several available continuous markers. In fact, under some assumptions, those methods could be extended to develop a decision rule from multiple continuous-scale tests. For example, Su-Liu's linear discriminant method is still applicable with the parameters in the normal distributions estimated through the maximum likelihood method using the EM algorithm [35] . Our aim in this paper is to derive an optimal composite test in a sequential way. The optimal sequential composite test is described in Section 2, and applied to the motivating ELISA data in Section 3. The statistical properties are explored through simulation studies in Section 4. We conclude this paper by discussion in Section 5.
Optimal sequential composite test without a gold standard
For simplicity in illustration, suppose that there are two quantitative diagnostic tests on each subject and for each test, a greater value of the result indicates a larger chance of case. Denote X i as the random variable representing the result from test i for i = 1, 2 and D as the random variable indicating the case presence, with D = 1 meaning case present and D = 0 meaning case absent. Moreover, F 1 and F 0 are the joint distribution functions of X = (X 1 , X 2 ) for the case and non-case populations, respectively, and f 1 and f 0 are the corresponding probability density functions. Statistics in Medicine J. ZHANG ET AL.
Model setup
Suppose Test 1 is superior to Test 2 judged by a greater value of AUC. The decision rule driven by the sequential composite test is determined by a pair of cut-off values (C 1 , C 2 ) such that:
1. if X 1 > C 1 , then this subject is classified as positive for the study event; else, 2. if X 2 > C 2 , then classified as positive; 3. otherwise, classified as negative.
It is theoretically equivalent to the "believe the positive" (BP) rule defined in Marshall [26] and Politser [27] given the threshold values C 1 and C 2 .
Given the cut-off (C 1 , C 2 ), the sensitivity and specificity for evaluating this composite test can be expressed as follows:
Equations (2) and (3) are actually equivalent to (1) assuming that neither p 1 nor p 2 is pre-fixed. We are searching for the optimal sequential composite test in the sense that it achieves the maximum sensitivity among all the sequential composite tests whose specificity is fixed at p 0 . Based on (2) and (3), this task can be converted to a constrained non-linear optimization problem:
An efficient algorithm for finding the optimal (C 1 , C 2 ) in (4) is essential in the development of this sequential method.
Estimation and statistical inferences 2.2.1. MLE of multivariate normal model
Suppose we have a sample of results from two quantitative diagnostic tests X 1 , X 2 , · · · , X n that are assumed to be independent and identically distributed copies of X with distribution F . The implementation of all the foregoing methods requires estimation of F 1 and F 0 from observed data in the first place. Here we follow the set-up of Su and Liu's method [24] for the distribution of the tests results X, i.e.
A mixture distribution of F 1 and F 0 is adopted to model the observed data, that is
where π is an unknown parameter indicating the mixture proportion, or equivalently, the case prevalence, and θ = (π, θ 1 , θ 0 ) = (π, (µ 1 , V 1 ), (µ 0 , V 0 )) denotes the model parameters. The log-likelihood of the observed data can be expressed as: We note that if the gold standard does exist so that the exact memberships D = (D 1 , . . . , D n ) are known, the log likelihood for the augmented data
and
.
Hence the MLE of the model parametersθ n is easily computed using the EM algorithm [35] due to its numerical stability and algorithmic convenience for this problem. The details of the EM algorithm are provided in Appendix A.
Computation of the optimal sequential composite test
Under the normality assumption, the feasible set of (C 1 , C 2 ) defined by a given specificity F 0 (C 1 , C 2 ) = p 0 constitutes a convex contour curve [36] . When the diagnostic markers are more variant for the case subjects, it is expected that the contour given by F 1 (C 1 , C 2 ) = t is also convex but with less curvature and moves towards the origin of (C 1 , C 2 ) domain as t decreases. The optimization problem (4) can be illustrated geometrically in Figure 1 . As seen in Figure 1 , the constrained optimal value t corresponds to the value given by the contour that touches the Statistics in Medicine
for the decision rule is simply the tangent point of the two contour lines and can be uniquely determined. Therefore, the original optimization problem (4) is converted to solving the system of bivariate nonlinear equations (7) for the tangent point of the contour lines of F 1 and F 0 .
The first equation represents the constraint given by the fixed specificity and the second equation reflects that the two contour lines have the same gradient at the tangent point. The Newton-Raphson method with the step-halving line search procedure is utilized to solve the system.
LetĈ n = (Ĉ 1n ,Ĉ 2n ) denote the solution of (7) with the MLE of θ,θ n = (θ 1n ,θ 0n ), then the sensitivity is estimated by
Asymptotic properties
Suppose θ 0 is the true vector of the model parameters under the mixture of bivariate normal distribution. Assuming that the regularity conditions for MLE hold, it is known that as n → ∞,θ n → P θ 0 , and
where I is the Fisher information matrix given by −E
. For the optimal sequential composite test, let C 0 = (C 10 , C 20 ) denote the solution of the system (7) under θ = θ 0 , then the true sensitivity is sen C = 1 − F 1,θ10 (C 10 , C 20 ). The estimated sensitivity sen C is consistent and asymptotically normal under the mild condition (8) given in Theorem 2.1. The proof of the theorem is also deferred to Appendix B Theorem 2.1 If F 0 and F 1 are continuously differentiable with respect to C = (C 1 , C 2 ) and θ and satisfy the following inequality (8) at C 0 and θ 0 ,
then as sample size n → ∞, √ n ( sen C − sen C ) converges to a normal distribution with mean 0 and variance given by (B.1).
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An analysis of the ELISA data
The optimal sequential composite test based on the two ELISAs is applied to classify the 100 independent blood samples for the presence of E2 antibody in the motivating data example. Assuming the mixture of two bivariate normal models is true for this data example, the model-based estimated ROC curves are depicted in Figure 3 
The optimal linear composite test for comparison is applicable here by extending the Su-Liu's method [24] under the assumption of normality. The technical details of the extended optimal linear composite test are referred to Zhang [39] . At the specificity of 90%, the ith sample is diagnosed as positive if X 1i > 0.24 using test 1 alone, X 2i > 0.41 using test 2 alone, 1.2X 1i + 0.8X 2i > 0.57 under the optimal linear composite test and X 1i > 0.27 or X 2i > 0.43 under the optimal sequential composite test, where X 1i and X 2i are the results from test 1 and test 2 on the ith sample. If the future data set is the same as the data used to derive the classification rules, the classifications based on both composite decision rules are represented in Figure 2 . The diagnoses from the two composite test do not disagree too much except that the linear composite test tends to attribute more samples into the E2 antibody negative group. We also plot the ROC curves for the two composite tests shown in Figure 3 . Combining the two tests into a composite test does improve the discriminant capability compared to any individual test. This improvement is possible because we allow the cut-off value for each of the tests when used as a composite is different from the cut-off value when used individually. The improvement from the linear composite test is not as substantial as the sequential composite test. It appears that the sequential test is superior to the linear composite test at all values of specificity for this case. Moreover, the optimal sequential composite test only needs 53% of the blood samples for the second test at average over 1000 bootstrap samples. This implies that under the optimal sequential composite test, the probability that a patient needs to be tested by T2 is only about 50%. Hence it has a profound significance in practice when the tests are expensive or present some strong side effects.
Simulation studies
Simulations on the model-based estimate of sensitivity for the proposed optimal sequential composite test
In this section, we conduct simulation studies to assess the statistical properties of the model-based sensitivity for the proposed optimal sequential composite test. We generate two diagnostic markers for the case group from a bivariate normal distribution N (µ 1 , V 1 ) of The values of the parameters in the model are selected to mimic our motivating ELISA data example. A sample of 100 simulated data is shown in Figure 4 . With the parameter values given above, the sensitivities at specificities 80% and 90% are 71% and 64%, respectively, for Three total sample sizes (100, 200 and 400) and two different case prevalence values (0.25 and 0.5) are examined, respectively. At each combination of sample size and case prevalence, sample data are generated from the underlying mixture of two bivariate normal models. The exact sensitivity of the optimal sequential composite test at a given specificity is computed by solving the nonlinear system (7) with the bivariate normal distribution functions F 0 and F 1 , and similarly, the exact sensitivity of the optimal linear composite test is calculated using the true parameters in the bivariate normal distributions as depicted by Su and Liu [24] . The model-based sensitivities are estimated with F 1 and F 0 replaced by their MLE,F 0 andF 1 . The standard error of the estimated sensitivity is obtained via the nonparametric bootstrap method aforementioned and its 95% Wald confidence interval is constructed using the bootstrap standard error. Subsequently, the bias, root mean square error (RMSE) and coverage probability of the 95% Wald confidence interval (CP) are calculated. In addition, the empirical sensitivity (Esen) and specificity (Espe) are assessed since the true case status is known in simulations. We repeat the Monte-Carlo simulation for 1000 times for each combination of the sample size and case prevalence, and the results are summarized in Table 1 .
Indicated by Table 1 , the composite tests perform generally better than an individual test and the optimal sequential composite test is superior to the optimal linear composite test in view of the sensitivities for a given specificity. Under the correct normal mixture model, as the sample size increases, the bias of the model-based sensitivity tends to be negligible and the coverage probability tends to arrive at the nominal value 95%, asserting the asymptotic properties declared by Theorem 2.1. Our simulation study indicates for a study with small sample size of 100 as in the ELISA study in Section 3, the estimated sensitivity of the derived optimal sequential composite test is fairly accurate with a negligible bias as illustrated by Table 1 . The corresponding classification results are also reliable as illustrated by Table 1 , because both the empirical sensitivity and specificity closely agree to their designed values. However making the model-based inference about the sensitivity needs a caution as the coverage probability is systematically lower than its target value (95%). It is also inferred by the RMSE that the estimated sensitivity may be more precise with a higher case prevalence. 
Simulations on the classification accuracy of the proposed sequential composite test
In our motivating example, the true GBV-C status is unknown. A series of simulations are carried out to study the accuracy and robustness of the prediction on a new dataset by the proposed composite classification rule. The simulation study is designed in the following steps:
1. Simulate a training dataset by the two settings, respectively:
(a) The two markers follow the same mixture of two bivariate normal distributions as in Section 4.1.
(b) The two markers follow a mixture of two Gaussian copulas with student-t marignals (4 degrees of freedom; parameters are scaled to retain the values of means and variances in the bivariate normal distributions above).
The case prevalence is 0.5 in both settings. • Fit the data by the bivariate normal mixture model (5).
• Use the MLE to derive the classification rules for one single marker, the optimal linear composite test and the optimal sequential composite test under two specificities, 0.8 and 0.9.
• Simulate one testing dataset with the same sample size and the same simulating distribution as the training data, for each of the three values of the case prevalence, 0.25, 0.5 and 0.75.
• Apply the classification rules to each testing set and calculate the true positive fraction (TPF) and true negative fraction (TNF).
3. Repeat steps above for 1000 times, for each of the three sample sizes (100, 200 and 400). Table 2 listed the TPFs and TNFs of the three classification rules averaged over the 1000 experiments. The test based on one single marker alone has a poor discriminating power. Both composite tests improve the accuracy substantially in terms of a higher TPF under the pre-specified specificities in the training set. The optimal sequential composite test outperforms the other two tests with the highest TPF and the accordant TPF, even when the multivariate normal assumption is violated (Setting b). Note that when normal assumption holds (Setting a), the empirical sensitivities of both composite tests in the testing set approach to the exact value as the sample size goes up.
Under both settings, different case prevalences in the new data do not affect the classification accuracy, but the optimal sequential test would be more efficient when applied to a data with a greater case prevalence since more subjects can be identified as case by one test at the first step of the test.
Discussion
In this paper, we develop a classification method from an alternative perspective based on multiple quantitative tests without a gold standard. The constitution of the optimal sequential composite test is statistically equivalent to the implementation of a sequence of tests discussed by Thompson [25] . Illustrated by the real data application and simulation studies, for the data of the pattern shown in Figures 2 and 4 , the optimal sequential composite test demonstrates a considerable improvement in the discriminating power between case and non-case in view of the area under the ROC curve (AUC). Moreover, it has an additional advantage of engaging fewer tests. This is especially desired when the tests are costly or not applicable to all study subjects under some circumstances. The optimality of the composite test in this article is purely based on the classification accuracy without considering risk or cost associated with the tests. Some modifications of the optimizing system for the decision rule is needed if the risk or cost ought to be considered for determining an optimal decision rule in some applications.
The sequential composite test in this work uses the "believe the positive" rule based on the biological mechanism in our motivating example. It can be constructed by the "believe negative" rule accordingly in other applications. Also there has been some works in the framework of group sequential design to evaluate diagnostic tests with a gold standard [40, 41] . Further topics could be to generalize this method to the design of clinical trials.
The sequential classification method is illustrated with two tests throughout the paper but it can be similarly designed for the situation with more than two tests. It is, however, a mathematically challenging problem because finding the optimal cut-off values may not be equivalently converted to the problem of solving a nonlinear system as it does for the two-test case. The grid search is a straightforward option but it can be very numerically inefficient, especially for high dimensional data. There is still a space for improving the numerical algorithm in order to accommodate an arbitrary number of tests.
The proposed method has a fundamental assumption of multivariate normal distribution for the test results in both case and non-case groups. This assumption is likely violated in applications. In our second simulation study, when the distributional assumption is violated, the predication based on the mis-specified model is quite accurate. When the data are Statistics in Medicine J. ZHANG ET AL. and G(g(θ), θ) = 0 for all θ ∈ U . Based on the MLE properties, it is known thatθ n → p θ 0 and √ n(θ n − θ 0 ) → d N (0, I −1 ). So for any ǫ > 0 and δ > 0,
there exists an N , such that n > N , Pr(|θ n − θ 0 | > δ) < ǫ. This implies that for any n > N ,θ n ∈ U in probability, and hence the proposed method for finding the cut-offĈ n = (Ĉ n,1 ,Ĉ n,2 ) through solving for G(Ĉ n ,θ n ) = 0 results in C n = g(θ n ) in probability. Further note that F 1 (C, θ) = F 1 (g(θ), θ) is a continuously differentiable function of θ, and consequently, by the continuous mapping theorem and the delta method, we have
where
